QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2020, QIAGEN employed more than 5,600 people in over 35 locations worldwide.

Company profile
Ticker
QGEN
Exchange
Website
CEO
Thierry Bernard
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...
Former names
QIAGEN NV
SEC CIK
QGEN stock data
Latest filings (excl ownership)
SD
Conflict minerals disclosure
30 May 23
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
5 May 23
6-K
Current report (foreign)
4 May 23
6-K
Current report (foreign)
4 May 23
20-F
2022 FY
Annual report (foreign)
10 Mar 23
6-K
Current report (foreign)
9 Feb 23
6-K
Current report (foreign)
8 Nov 22
6-K
Current report (foreign)
8 Nov 22
6-K
Current report (foreign)
8 Nov 22
6-K
Current report (foreign)
28 Jul 22
Transcripts
QGEN
Earnings call transcript
2023 Q1
4 May 23
QGEN
Earnings call transcript
2022 Q4
8 Feb 23
QGEN
Earnings call transcript
2022 Q3
8 Nov 22
QGEN
Earnings call transcript
2022 Q2
29 Jul 22
QGEN
Earnings call transcript
2022 Q1
28 Apr 22
QGEN
Earnings call transcript
2021 Q4
9 Feb 22
QGEN
Earnings call transcript
2021 Q3
4 Nov 21
QGEN
Earnings call transcript
2021 Q1
5 May 21
QGEN
Earnings call transcript
2020 Q4
10 Feb 21
Latest ownership filings
SC 13G/A
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
8 Feb 23
SC 13G/A
BlackRock Inc.
23 Jan 23
SC 13G/A
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
2 Feb 22
SC 13G/A
BlackRock Inc.
27 Jan 22
SC 13G
BlackRock Inc.
26 Jan 22
SC 13G/A
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
11 Feb 21
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
3 Feb 21
SC 13G/A
BlackRock Inc.
26 Jan 21
SC 13D/A
DAVIDSON KEMPNER PARTNERS
22 Jan 21
SC 13D
DAVIDSON KEMPNER PARTNERS
3 Aug 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2023
56.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 276 |
Opened positions | 34 |
Closed positions | 51 |
Increased positions | 107 |
Reduced positions | 90 |
13F shares | Current |
---|---|
Total value | 5.74 tn |
Total shares | 129.47 mm |
Total puts | 410.40 k |
Total calls | 377.00 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Massachusetts Financial Services | 21.20 mm | $973.55 bn |
Vanguard | 8.46 mm | $388.45 bn |
BLK Blackrock | 7.66 mm | $351.79 bn |
Amundi | 4.59 mm | $210.52 bn |
Deutsche Bank AG - Registered Shares | 4.39 mm | $201.69 bn |
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 3.49 mm | $158.73 bn |
MS Morgan Stanley | 3.19 mm | $146.55 bn |
FIL | 3.06 mm | $139.23 bn |
GS Goldman Sachs | 2.98 mm | $136.74 bn |
DekaBank Deutsche Girozentrale | 2.89 mm | $130.78 mm |
Press releases
QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk
3 May 23
QIAGEN launches QIAstat-Dx in Japan with respiratory panel for syndromic testing
24 Apr 23
QIAGEN announces expansion of Supervisory Board
20 Apr 23
QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023
14 Apr 23
QIAGEN's QIAxcel Connect wins Red Dot design award
29 Mar 23